Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature

1477-7819-5-75 1477-7819 Review Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature Jones E Gregory gregedjones@yahoo.co.uk Strauss C Dirk dirkcstrauss@yahoo.co.uk Forshaw J Matthew mjforshaw@doctors.org.uk Deere Harriet Harriet.Deere@gstt.nhs.uk Mahedeva Ula Ula.Mahadeva@gstt.nhs.uk Mason C Robert Robert.Mason@gstt.nhs.uk

Department of General Surgery, Guy's and St Thomas' NHS Trust, St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH, UK

Department of Histopathology, Guy's and St Thomas' NHS Trust, St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH, UK

World Journal of Surgical Oncology 1477-7819 2007 5 1 75 http://www.wjso.com/content/5/1/75 17620117 10.1186/1477-7819-5-75 27 2 2007 09 7 2007 09 7 2007 2007 Jones et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The stomach is an infrequent site of breast cancer metastasis. It may prove very difficult to distinguish a breast cancer metastasis to the stomach from a primary gastric cancer on the basis of clinical, endoscopic, radiological and histopathological features. It is important to make this distinction as the basis of treatment for breast cancer metastasis to the stomach is usually with systemic therapies rather than surgery.

Case presentations

The first patient, a 51 year old woman, developed an apparently localised signet-ring gastric adenocarcinoma 3 years after treatment for lobular breast cancer with no clinical evidence of recurrence. Initial gastric biopsies were negative for both oestrogen and progesterone receptors. Histopathology after a D2 total gastrectomy was reported as T4 N3 Mx. Immunohistochemistry for Gross Cystic Disease Fluid Protein was positive, suggesting metastatic breast cancer. The second patient, a 61 year old woman, developed a proximal gastric signet-ring adenocarcinoma 14 years after initial treatment for breast cancer which had subsequently recurred with bony and pleural metastases. In this case, initial gastric biopsies were positive for both oestrogen and progesterone receptors; subsequent investigations revealed widespread metastases and surgery was avoided.

Conclusion

In patients with a history of breast cancer, a high index of suspicion for potential breast cancer metastasis to the stomach should be maintained when new gastrointestinal symptoms develop or an apparent primary gastric cancer is diagnosed. Complete histopathological and immunohistochemical analysis of the gastric biopsies and comparison with the original breast cancer pathology is important.

Background

Metastatic spread to the upper gastrointestinal tract is infrequently reported with cancers of the breast, lung, kidney and malignant melanoma 1. The most common sites of breast cancer metastasis are the skeleton, lungs and the liver; the stomach, peritoneum, colon, retroperitoneum and the small bowel have all been reported as potential sites of metastatic involvement 2. Metastatic spread to the stomach may occur many years after the initial treatment for breast cancer. It may prove very difficult to distinguish from a primary gastric cancer on clinical, endoscopic, radiological and histopathological features 345. However, it is important to make this distinction as the basis of treatment for breast cancer metastasis to the stomach is usually with systemic therapies rather than surgery 67.

The authors present two cases of breast cancer metastasis to the stomach, both of which were initially considered to represent primary gastric cancer. The authors also review current literature with a particular emphasis on the utility of immunohistochemistry in differentiating between primary gastric cancer and gastric metastasis from breast cancer.

Case Presentations

Patient 1

A fifty-one year old woman presented with weight loss and vague epigastric pain. Three years previously, she had undergone a wide local excision and axillary dissection for a right sided breast lump. Postoperative histology showed a completely excised grade II invasive carcinoma (T2) with associated intermediate grade DCIS. On immunohistochemistry, the tumour was found to be positive for both oestrogen and progesterone receptors but negative for E-cadherin, suggesting a predominantly lobular tumour type; all eight excised lymph nodes were clear of metastases (N0). She had subsequently received adjuvant radiotherapy to the breast. As she was unable to tolerate either tamoxifen or anastrozole due to side effects (persistent hot flushes), surgical oophorectomy had been performed. She required tibolone to treat menopausal symptoms. She had been regularly reviewed in breast clinic without any clinical evidence of recurrence.

She was initially investigated with an upper gastrointestinal endoscopy. This demonstrated only small antral polyps, which were biopsied (Figure 1). Histology revealed gastric mucosa infiltrated by poorly differentiated adenocarcinoma of a signet-ring pattern, with immunostaining negative for oestrogen, progesterone receptors and Her-2. Due to the unexpected nature of these findings, a further upper gastrointestinal endoscopy was performed with repeat biopsies from both proximal and distal stomach which, again, were consistent with signet-ring type adenocarcinoma (Figure 2). Computed tomography (CT) could not define a definite primary gastric cancer; there was no evidence of lymph node or metastatic spread (Tx N0 M0).

Figure 1

Endoscopic view of antral polyps in patient 1, biopsies of which confirmed signet-ring adenocarcinoma

Endoscopic view of antral polyps in patient 1, biopsies of which confirmed signet-ring adenocarcinoma.

Figure 2

Endoscopic view of fundal polyp in patient 1, biopsies of which confirmed signet-ring adenocarcinoma

Endoscopic view of fundal polyp in patient 1, biopsies of which confirmed signet-ring adenocarcinoma.

The patient was counselled for radical curative surgery in view of an apparent localised primary gastric cancer. A D2 total gastrectomy with Roux-en-Y reconstruction was performed and the patient made an uneventful postoperative recovery. Post operative histology revealed a poorly differentiated adenocarcinoma of the stomach, invading into the duodenum, with 40 out of 41 lymph nodes involved (pT4 N3 Mx). Immunohistochemistry performed on the stomach and lymph nodes was positive for CK7 and GCDFP (Gross Cystic Disease Fluid Protein) (Figure 3) and negative for CK20, E-cadherin and Her-2. The tumour in the lymph nodes, but not the stomach, was strongly positive for both oestrogen and progesterone receptors. Consequently, the diagnosis was revised to metastatic breast cancer. The patient was considered for further hormonal therapy. Subsequently she developed widespread bony metastases. She is currently receiving bisphosphonates and palliative care.

Figure 3

An invasive adenocarcinoma is present in the gastrectomy specimen from patient 1

An invasive adenocarcinoma is present in the gastrectomy specimen from patient 1. Numerous signet ring cells are seen in the gastric wall (panel A). Carcinoma cells are immunohistochemically positive for CK7 (panel B) and gross cystic disease fluid protein (GCDFP) (panel C). Metastatic carcinoma cells in the lymph node (panel D) are also positive for GCDFP (insert).

Patient 2

A sixty-one year old woman had undergone a mastectomy and axillary dissection for a left sided breast cancer fourteen years previously. Postoperative histology revealed a grade III 4 × 2 × 2 cm infiltrating lobular carcinoma; the tumour was positive for both oestrogen and progesterone receptors but negative for E-cadherin. Fourteen out of fifteen sampled lymph nodes contained metastases. The patient then received adjuvant chemotherapy, radiotherapy to the breast and five years' treatment with tamoxifen. She remained disease free on follow up until one year ago when she was diagnosed with bony metastases and a malignant pleural effusion. This was treated with paclitaxel chemotherapy, followed by letrozole and ibandronate, with symptomatic improvement and apparent disease remission.

Nine months after this recurrence she presented with progressive dysphagia and weight loss. An upper gastrointestinal endoscopy revealed a tumour arising from the gastro-oesophageal junction and occupying the lesser curve of the anterior gastric wall. Biopsies revealed a poorly differentiated adenocarcinoma of signet ring cell type. CT showed an extensive gastric cancer just below the oesophagogastric junction without any obvious lymph node or metastatic spread; this was staged as T3 N0 M0 (Figure 4).

Figure 4

CT abdomen with oral contrast in patient 2 demonstrating thickening below the oesophagogastric junction (indicated by arrow) and residual right sided pleural effusion

CT abdomen with oral contrast in patient 2 demonstrating thickening below the oesophagogastric junction (indicated by arrow) and residual right sided pleural effusion.

She was referred to our unit for a surgical opinion. She was planned for a staging laparoscopy but, before this could be performed, she developed a left sided upward gaze. CT scan of the brain showed a left retro-orbital space occupying lesion consistent with a metastasis. Immunohistochemistry on the biopsies from the stomach became available at this stage and were positive for both oestrogen and progesterone receptors (CK7, ER and PR positive; CK20 and Her-2 negative), consistent with metastatic breast carcinoma (Figure 5). Further surgical intervention was avoided and the patient has received further chemotherapy and radiotherapy to her brain.

Figure 5

Gastric biopsy from patient 2 is infiltrated by a poorly differentiated adenocarcinoma with signet ring cell morphology (panel A)

Gastric biopsy from patient 2 is infiltrated by a poorly differentiated adenocarcinoma with signet ring cell morphology (panel A). Immunohistochemistry showing positive staining for CK7 (panel B), oestrogen receptor (panel C) and progesterone receptor (panel D).

Discussion

Both of the patients in this report were initially diagnosed with an apparent primary gastric cancer. Ultimately this diagnosis was revised to metastatic breast cancer, but only after surgery had been performed in patient 1. The incidence of breast cancer metastasis to the stomach in long term follow up and post mortem studies has been estimated at 2–18% 36891011. This may occur many years after the diagnosis of the primary breast lesion and, in 90 – 94% of patients, there will be concurrent sites of breast cancer metastasis 67. Patient 2 had been treated for recurrent breast cancer prior to her presentation with a gastric tumour.

The clinical presentation of a breast cancer metastasis to the stomach is often indistinguishable from primary gastric cancer, as seen in the two patients in this report. Common symptoms include dyspepsia, anorexia, epigastric pain, early satiety, vomiting and bleeding. The most common pattern of breast cancer metastasis to the stomach is a linitis plastica with diffuse infiltration of the submucosa and muscularis propria; less commonly, discrete nodules or external compression may occur 7. Madeya and Borsch reported that 73% of patients with gastric metastases had diffuse intramural infiltration imitating linitis plastica 12. Diffuse infiltration of the stomach is characteristic of metastases from invasive lobular carcinoma: Taal et al reported that 83% of patients with gastric metastasis had lobular breast carcinoma as the primary pathology 6. Patient 1 had a linitis plastica type pattern whereas patient 2 had a discrete proximal gastric lesion.

A high index of suspicion for metastatic breast cancer should be maintained when a patient develops gastric pathology with a history of breast cancer. Endoscopic, radiological and histological evaluation is essential to discriminate between primary gastric cancer and breast cancer metastasis to the stomach. Macroscopic endoscopic findings are usually unhelpful in identifying the underlying pathology. Since metastatic gastric infiltration is frequently limited to the submucosa and seromuscular layer, endoscopic evaluation may be normal in 50% of cases or only show discrete mucosal abnormalities indistinguishable from other tumours or benign disease 13. Radiological findings on computed tomography or barium studies include encasement of the whole stomach as seen in linitis plastica, multiple lesions of the stomach or extrinsic lesions of the gastric wall 4. Deep and extensive biopsies should be performed at endoscopy. Their histology should be compared with the primary breast cancer pathology as the histologic picture may be similar. However, lobular carcinoma of the breast may produce a signet ring morphology which can be confused with a primary signet ring or diffuse-type gastric adenocarcinoma 7. Both of the patients in this study had been previously treated for lobular breast cancer.

Detailed immunohistochemical analysis may be the only consistent method for differentiating between metastatic and primary gastric carcinoma. Although oestrogen and progesterone receptor positivity in the gastric biopsies suggest breast cancer metastasis to the stomach, it is worth noting that oestrogen and progesterone receptor positivity have been reported in 32% and 12% of patients with primary gastric cancer 14. However, these findings are based upon studies using first-generation antibodies against Oestrogen receptor β (ERβ) which are no longer used in standard practice. Taal et al investigated whether immunohistochemical detection with second-generation antibodies against Oestrogen receptor α (ERα) can be used to diagnose gastric metastasis of breast carcinoma 15. In their study none of the primary gastric carcinomas expressed ERα. Moreover, no cases with an ER- primary breast carcinoma and an ERα+ carcinoma in a gastric biopsy specimen were found. Therefore they concluded that ERα expression can be reliably used to diagnose gastric metastasis of breast carcinoma. They also investigated if the expression pattern of E-cadherin could be of help in the differential diagnosis of primary gastric cancer versus metastatic breast carcinoma. In their study absence of E-cadherin staining was significantly related to metastatic breast carcinoma. It appears that the absence of E-cadherin expression in an adenocarcinoma in a gastric biopsy should raise the possibility of metastatic breast carcinoma and ERα positivity can be reliably used to diagnose gastric metastasis of breast carcinoma.

The absence of positive oestrogen and progesterone receptors in patient 1's gastric biopsies led to the initial assumption that this was a primary gastric cancer. Positive monoclonal staining with GCDFP-15 (gross cystic disease fluid protein-15) has been found to be a sensitive (55–76%) and specific (95–100%) marker to correctly identify a malignant lesion as metastatic breast carcinoma 5161718192021. This marker is a monoclonal antibody of gross cystic disease fluid protein-15 (GCDFP-15) which is detected in macroscopic breast cyst fluid and in the plasma of patients with breast cancer 2223. There is an excellent correlation between GCDFP-15 positivity and the origin of a metastatic breast adenocarcinoma 17. Wick demonstrated reactivity for GCDFP-15 in 76 of 105 breast carcinomas (72%) 16. The diagnosis of metastatic breast cancer in patient 1 was eventually confirmed on the basis of GCDFP immunohistochemistry.

In common with other sites of metastatic breast cancer, breast cancer metastasis to the stomach should be treated systemically 7. The choice of systemic treatment is based upon presenting symptoms, age, general performance status, receptor status and previous systemic treatments. The response rate to chemotherapy and hormonal therapy varies: the median survival in two small series of patients receiving systemic treatment for breast cancer metastasis to the stomach and gastrointestinal tract varied between 10 and 28 months 624. In a series of 51 patients with gastric metastases from the breast, hormonal therapy (27%) was performed almost as frequently as chemotherapy (33%) 7. The options for hormonal therapy included tamoxifen, oophorectomy or progesterone as first-line treatment, and aminogluthetimide, androgens or prednisolone as second line treatment. New anti-hormonal drugs also include aromatase inhibitors and GNRH analogues in pre-menopausal patients. Although combination cyclophosphamide, methotrexate and 5-fluorouracil (CMF) tends not to be used in the metastatic setting, new anti-neoplastic drugs are now available and include taxanes, capecitabine and trastzumab if c-erbB2 is positive.

One study has shown that a partial remission with a clear palliative effect can be obtained in only 46% of patients receiving systemic therapy with no obvious difference in response rates between hormonal treatment and chemotherapy. It is worth noting that symptomatic treatments alone such as acid reduction could only be performed in 20% of the patients in this study due to their poor general condition or extensive prior treatment 7. McLemore et al reported a median overall survival after diagnosis of 28 months in 73 patients with breast cancer metastasis to the gastrointestinal tract 24: whilst advanced age at diagnosis and gastric metastasis had a negative effect on survival, treatment with systemic chemotherapy or tamoxifen had a positive effect on survival. It is worth noting that there is a low response rate to chemotherapy in invasive lobular carcinoma patients which must be must taken into consideration when choosing the most appropriate treatment 25.

The complications of breast cancer metastasis to the stomach can be managed in a similar manner to primary gastric cancer: endoluminal stents can be used for gastric outlet obstruction; bleeding may be controlled by endoscopic or endovascular therapy 262728293031. Although surgical resection has been considered in selected patients, the role of surgery is usually limited as the gastric metastasis reflects systemic disease 632. Palliative surgery has not been shown to affect overall survival 24. Surgery should be limited to palliative bypass in those patients where less invasive measures fail to palliate their gastric outlet obstruction.

Conclusion

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

GE Jones Collected data and wrote "Case presentations" section.

DC Strauss Researched the literature and wrote "Discussion" section.

MJ Forshaw Edited and revised the manuscript.

H Deere Provided histopathological diagnoses and revised the manuscript.

U Mahadeva Provided histopathological diagnoses and revised the manuscript.

RC Mason Consultant responsible for the care of the patients and is the guarantor of the manuscript.

All authors have read and approved the manuscript.

Acknowledgements

Consent was obtained from both patients for the publication of the study.

The authors gratefully acknowledge Dr Fuju Chang who produced the photomicrographs of the two cases.

Metastatic disease involving the stomach Menuck LS Amberg JR Am J Dig Dis 1975 20 903 13 10.1007/BF01070875 1190198 Metastatic lobular carcinoma of the breast: Patterns of spread in the chest, abdomen and pelvis on CT Winston CB Hadar O Teitcher JB Caravelli JF Sklarin JF Panicek DM Liberman L Am J Roentgenol 2000 175 795 800 Metastatic breast cancer masquerading as gastrointestinal primary Schwarz RE Klimstra DS Turnbull ADM Am J Gastroenterol 1998 93 111 114 10.1111/j.1572-0241.1998.111_c.x 9448188 Breast cancer masquerading as a primary gastric carcinoma Tremblay F Jamison B Meterissian S J Gastrointest Surg 2002 6 614 6 10.1016/S1091-255X(01)00006-3 12127129 Gastric metastasis of mammary signet ring cell carcinoma: a differential diagnosis with primary gastric signet ring cell carcinoma Yim H Jin YM Shim C Park HB JKMS 1997 12 256 261 The spectrum of gastrointestinal metastases of breast carcinoma. 1. Stomach Taal BG den Hartog Jager FC Steinmetz R Peterse H Gastrointest Endosc 1992 38 130 135 1568608 Clinical presentation, endoscopic features, and treatment of gastric metastases from breast carcinoma Taal BG Peterse H Boot H Cancer 2000 89 2214 21 10.1002/1097-0142(20001201)89:11<2214::AID-CNCR9>3.0.CO;2-D 11147591 Linitis plastica caused by metastatic lobular carcinoma of the breast Cormier WJ Gaffey TA Wech JM Wech JS Edmonson JH Mayo Clin Proc 1980 55 747 753 6261047 Gastric and colonic metastases from breast cancer Klein MS Sherlock P Dig Dis Sci 1972 17 881 886 10.1007/BF02239526 Signet ring variant of lobular carcinoma of the breast: A clinicopathologic and immunohistochemical study Raju U Ma CK Shaw A Mod Pathol 1993 6 516 520 8248106 Breast cancer metastatic to the stomach Davis HL Murray RK Korbitz BC Am J Dig Dis 1968 13 868 73 10.1007/BF02237571 5303029 Gastrointestinal metastases of breast carcinoma [letter] Madeya S Börsch G Gastrointest Endosc 1993 39 103 104 8267696 Metastatic gastric cancer arising from breast carcinoma: endoscopic ultrasonographic aspects Lorimier G Binelli C Burtin P Maillart P Bertrand G Verriele V Fondrinier E Endoscopy 1998 30 800 804 9932762 The prognosis of patients with gastric cancer possessing sex hormone receptors Matsui M Kojima O Kawakami S Uehara Y Takahashi T Surg Today 1992 22 421 425 10.1007/BF00308791 1421863 Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma Van Velthuysen M-LF Taal BG Van der Hoeven JJM Peterse JL Histopathology 2005 46 2 153 157 10.1111/j.1365-2559.2005.02062.x 15693887 Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin Wick MR Lillemoe TJ Copland GT Swanson PE Manivel JC Kiang DT Hum Pathol 1989 20 281 7 10.1016/0046-8177(89)90137-8 2542151 Immunohistochemistry of a breast gross cystic disease fluid protein (GCDFP-15): A marker of apocrine epithelium and breast carcinoma with apocrine features Mazoujian G Pinkus GS Davis S Am J Pathol 1983 110 105 111 6130702 Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study Raju U Ma CK Shaw A Mod Pathol 1993 6 516 20 8248106 Mammaglobin vs GCDFP-15: An Immunohistologic Validation Survey for Sensitivity and Specificity Bhargava R Beriwal S Dabbs DJ Am J Clin Pathol 2007 127 1 11 Utility of Immunohistochemistry in Distinguishing Primary Adenocarcinomas From Metastatic Breast Carcinomas in the Gastrointestinal Tract O'Connell FP Wang HH Odze RD Arch Pathol Lab Med 2005 129 338 347 15737028 Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast Honma N Takubo K Arai T Younes M Kasumi F Akiyama F Sakamoto G APMIS 2006 114 712 9 10.1111/j.1600-0463.2006.apm_434.x 17004974 A specific progesterone-binding component of human breast cyst fluid Pearlman WH Giueriguian JD Sawyer ME J Biol Chem 1973 248 5736 5741 4723913 Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients Haagensen DE Jr Mazoujian G Holder WD Jr Ann Surg 1977 185 279 285 1396606 843124 Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis McLemore EC Pockaj BA Reynolds C Gray RJ Hernandez JL Grant CS Donohue JH Ann Surg Oncol 2005 12 886 94 10.1245/ASO.2005.03.030 16177864 Primary systemic chemotherapy of invasive lobular carcinoma of the breast Katz A Saad ED Porter P Pusztai L Lancet Oncol 2007 8 1 55 62 10.1016/S1470-2045(06)71011-7 17196511 Self-Expanding Metal Stents for Gastroduodenal Malignancies: Systematic Review of their Clinical Effectiveness Dormann A Meisner S Vernin N Wenk Lang A Endoscopy 2004 36 543 550 10.1055/s-2004-814434 15202052 Gastroduodenal Stent Placement: Current Status Lopera JE Brazzini A Gonzales A Castaneda-Zuniga WR Radiographics 2004 24 1561 1573 10.1148/rg.246045033 15537965 Metastatic tumors to the stomach: Clinical and endoscopic features De Palma GD Masone S Rega M Simeoli I Donisi M Addeo P Iannone L Pilone V Persico G World J Gastroenterol 2006 12 7326 7328 17143949 Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases Oda I Kondo H Yamao T Saito D Ono H Gotoda T Yamaguchi H Yoshida S Shimoda T Endoscopy 2001 33 507 510 10.1055/s-2001-14960 11437044 Technique Review – Argon Plasma Coagulation and the Future Applications for Dual-Mode Endoscopic Probes Canady J Wiley K Ravo B Rev Gastroenterol Disord 2006 6 1 12 16520707 Endovascular intervention for the treatment of acute arterial gastrointestinal hemorrhage Funaki B Gastroenterol Clin North Am 2002 31 701 13 10.1016/S0889-8553(02)00025-0 12481726 Prognostically favorable abdominal breast cancer metastases with stomach involvement Akcali Z Sakalli H Ozyilkan O Demirhan B Haberal M Onkologie 2005 28 270 2 10.1159/000084652 15867484